Every 8-K that Propanc Biopharma, Inc. (PPCB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PPCB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PPCB filings page.
Propanc Biopharma, Inc. reported that effective July 8, 2026, Annie Van Broekhoven retired and stepped down from its Board of Directors, and the company accepted her resignation. The Board simultaneously filled the resulting vacancy.
The Board appointed Carlo Campiciano to serve as a director until his resignation or removal. Campiciano is a qualified accountant and member of the Institute of Public Accountants in Australia, with a Master of Entrepreneurship and Innovation and US GAAP certification. He previously served as CFO and Company Secretary of ASX-listed MedAdvisor Limited, where he helped raise multiple rounds of capital and supported the company’s ASX listing and international expansion. The company and Campiciano entered into a Director Agreement dated July 8, 2026, included as an exhibit.
Propanc Biopharma reported a board change. Effective February 20, 2026, long-serving director Dr. Julian Kenyon retired from the Board of Directors to focus on his personal and family life, but he will continue to support the company as a medical advisor.
The Board filled the resulting vacancy the same day by appointing Dr. Ralf Brandt as a new director. Dr. Brandt is an experienced pharmaceutical and oncology research executive with more than thirty years in drug discovery, angiogenesis, and pre-clinical development, and has advanced over 50 compounds to clinical studies.
Propanc BioPharma reported that on December 31, 2025 it received a Nasdaq notice that its common stock no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. This does not cause an immediate delisting. The company has 180 calendar days, until June 30, 2026, to regain compliance, which would occur if its stock closes at or above $1.00 for at least ten consecutive business days. Propanc may qualify for an additional 180‑day period if it meets other listing criteria and notifies Nasdaq it may cure the issue, potentially through a reverse stock split. If compliance is not restored and no extension or appeal succeeds, the stock could be delisted, which the company notes could reduce liquidity, hinder equity financing, limit access to public capital markets, and impair use of equity incentives. The company plans to monitor its bid price and evaluate options.
Propanc Biopharma (PPCB) closed a private placement with Hexstone Capital, receiving $1,000,099 in cash for 100 shares of Series C Preferred Stock and issuing a warrant to purchase up to 9,900 additional Series C Preferred shares at an exercise price of $10,000 per warrant share. The securities were issued under Section 4(a)(2) and Rule 506 of Regulation D.
The company also created and authorized up to 9,900 shares of Series C Preferred through a Certificate of Designation. Each preferred share has a stated amount of $10,000 and is convertible into common stock at the lesser of a fixed $5.00 per share or 85% of the lowest trading price during a defined period with a five trading day minimum and a volume condition. This brings in immediate cash and sets terms for potential future conversions and warrant exercises.
Propanc Biopharma (PPCB) entered a Securities Purchase Agreement for a private placement of a new Series C Preferred Stock class. The deal with Hexstone Capital provides for the issuance of 100 Series C Preferred shares at closing and a Warrant to purchase up to an additional 9,900 Series C Preferred shares. Each Series C Preferred share is convertible into common stock at the lesser of a fixed $5.00 per-share conversion price or 85% of the lowest trading price during a defined period tied to a holder’s conversion notice, with a five trading day minimum. The closing is conditioned on filing the Certificate of Designation for the Series C Preferred with Delaware.